Novo Nordisk files for regulatory approval of once-weekly

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes

Bagsværd, Denmark, 5 December 2016 - Novo Nordisk today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, for the treatment of adults with type 2 diabetes.

The submission is based on the results from the SUSTAIN clinical trial programme, which included more than 8,000 adults with type 2 diabetes. In the SUSTAIN programme, once-weekly semaglutide was studied in combination with oral-antidiabetic agents and basal insulin. Semaglutide demonstrated statistically significant and sustained blood glucose control compared to sitagliptin, exenatide extended-release, once-daily insulin glargine U100 and placebo. Furthermore, the cardiovascular outcomes trial, SUSTAIN 6, demonstrated a statistically significant cardiovascular risk reduction compared to placebo, as add-on to standard of care in patients with high cardiovascular risk. In addition, semaglutide demonstrated statistically significantly greater reductions in mean body weight versus comparators. 

Across the SUSTAIN clinical trial programme, once-weekly semaglutide had a safe and well tolerated profile with the most common adverse event being nausea.

"Achieving blood glucose control, weight loss and reducing the risk of cardiovascular events remains a significant challenge for adults with type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited with this regulatory filing, as results from the SUSTAIN programme show that once-weekly semaglutide has the potential to further improve the treatment of adults with type 2 diabetes."

About semaglutide Semaglutide is a new once-weekly analogue of human GLP-1 that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and food intake. Novo Nordisk intends to make once-weekly semaglutide available in a prefilled delivery device based on the same technology platform as FlexTouch ® .

Read the full announcement  

Further information

Media:    
Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors :    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

Company announcement No 86 / 2016 

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...fc6b731183

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 4

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 1

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 6

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 3

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 2

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 5

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading

Top 5 Most Recently Viewed Articles

Construction Leaders Unite to Combat Worker Suicide Crisis

Updated Category News Views 53

Construction Leaders Unite to Combat Worker Suicide Crisis In a significant move to address the alarming rate of suicide among construction workers, leading CEOs from prominent firms including Bechtel, Fluor, and Turner Construction Company have launched a new CEO Advisory Council. This initiative aims to drive awareness and develop effective solutions for mental health...

Continue Reading
Jack DiFranco Joins Woodward Park Partners Amid Growth Surge

Updated Category News Views 432

New Face, New Opportunities Talk about a shake-up! Woodward Park Partners just snagged Jack DiFranco, a heavyweight in the mergers and acquisitions arena. This isn’t just a name drop; we’re talking about 35 years of serious industry grind under his belt. DiFranco isn't just here to fill a seat; he’s got the chops to elevate this firm into a new realm of...

Continue Reading
BitMine's Ethereum Strategy Surges with $2 Billion in Holdings

Updated Category News Views 267

BitMine's Revolutionary Ethereum Holdings Strategy BitMine Immersion Technologies has achieved a remarkable milestone by surpassing $2 billion in Ethereum (ETH) holdings. This significant increase over the initial $250 million capital raise demonstrates the company's strong asset management and commitment to its treasury strategy. The journey began with a private...

Continue Reading
Fennec Pharmaceuticals Prepares for Q1 2025 Results Announcement

Updated Category News Views 139

Fennec Pharmaceuticals Set to Release Quarterly Financial Results RESEARCH TRIANGLE PARK, N.C. -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a dedicated specialty pharmaceutical company, has made an important announcement regarding its first quarter financial results for 2025. The company is on track to unveil these results before the U.S. financial markets...

Continue Reading
Stellantis Faces Lowest Italian Vehicle Production in Decades

Updated Category News Views 376

Stellantis and Its Production Challenges in Italy Stellantis (NYSE: STLA), the result of a major merger between iconic brands, is experiencing a notable decline in vehicle production within Italy. This setback is particularly concerning as it represents the lowest output levels this country has seen since 1956. Declining Production Figures Reported Recent data from union...

Continue Reading